Synaptophysin-like-1: A Novel Serum Diagnostic Marker for Pancreatic Ductal Adenocarcinoma Screening, Early Diagnosis, and Prognosis Prediction DOI Open Access
Sefa Ergün, Tevfik Avcı, Şeyma Dümür

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(11), С. 3719 - 3719

Опубликована: Май 26, 2025

Background: The role and underlying mechanisms of synaptophysin-like-1 (SYPL1), a neuroendocrine-associated protein, in pancreatic ductal adenocarcinoma (PDAC) remain unclear. This study aims to assess the diagnostic potential SYPL1 as serum biomarker for both resectable PDAC (rPDAC) metastatic (mPDAC) located at head pancreas. Additionally, levels were monitored patients who underwent surgical resection, with follow-up measurements taken 6 months postoperatively. Method: We analyzed healthy controls (n = 67), rPDAC 39), mPDAC 22), (6-month postoperative) 20) (due factors such relocation or death, 20 included instead 39 patients) by ELISA. Results: SYPL-1 showed significant differences across groups (controls: 7.43 ± 3.32, PC: 15.89 2.00, mPDAC: 20.01 4.03, p < 0.001). Both carcinoembryonic antigen (CEA) carbohydrate 19-9 (CA19-9) significantly greater cancer compared group. In decrease after surgery (p Strong correlations observed between tumor markers, CA19-9 showing positive correlation CEA (r 0.550, 0.001) 0.623, 0.002), while demonstrated negative −0.530, 0.009) mPDAC. Receiver operating characteristic (ROC) analysis revealed excellent performance distinguishing (AUC 0.965) 0.985) from controls, achieving superior accuracy conventional markers CA19-9. Conclusions: Serum emerges promising diagnosis monitoring Its elevated groups, coupled its marked following suggest that could play critical initial post-treatment surveillance. strong SYPL-1, CEA, further support utility multi-marker panel. Notably, high AUC values indicating ability distinguish controls. These findings highlight need investigation validate reliable, non-invasive enhance early detection, prognosis, treatment rPDAC.

Язык: Английский

Synaptophysin-like-1: A Novel Serum Diagnostic Marker for Pancreatic Ductal Adenocarcinoma Screening, Early Diagnosis, and Prognosis Prediction DOI Open Access
Sefa Ergün, Tevfik Avcı, Şeyma Dümür

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(11), С. 3719 - 3719

Опубликована: Май 26, 2025

Background: The role and underlying mechanisms of synaptophysin-like-1 (SYPL1), a neuroendocrine-associated protein, in pancreatic ductal adenocarcinoma (PDAC) remain unclear. This study aims to assess the diagnostic potential SYPL1 as serum biomarker for both resectable PDAC (rPDAC) metastatic (mPDAC) located at head pancreas. Additionally, levels were monitored patients who underwent surgical resection, with follow-up measurements taken 6 months postoperatively. Method: We analyzed healthy controls (n = 67), rPDAC 39), mPDAC 22), (6-month postoperative) 20) (due factors such relocation or death, 20 included instead 39 patients) by ELISA. Results: SYPL-1 showed significant differences across groups (controls: 7.43 ± 3.32, PC: 15.89 2.00, mPDAC: 20.01 4.03, p < 0.001). Both carcinoembryonic antigen (CEA) carbohydrate 19-9 (CA19-9) significantly greater cancer compared group. In decrease after surgery (p Strong correlations observed between tumor markers, CA19-9 showing positive correlation CEA (r 0.550, 0.001) 0.623, 0.002), while demonstrated negative −0.530, 0.009) mPDAC. Receiver operating characteristic (ROC) analysis revealed excellent performance distinguishing (AUC 0.965) 0.985) from controls, achieving superior accuracy conventional markers CA19-9. Conclusions: Serum emerges promising diagnosis monitoring Its elevated groups, coupled its marked following suggest that could play critical initial post-treatment surveillance. strong SYPL-1, CEA, further support utility multi-marker panel. Notably, high AUC values indicating ability distinguish controls. These findings highlight need investigation validate reliable, non-invasive enhance early detection, prognosis, treatment rPDAC.

Язык: Английский

Процитировано

0